---
title: Moderna CEO Stephane Bancel Bought $5 Million in MRNA Stock at $31 — His First Open-Market Purchase
type: news
slug: bancel-mrna-ceo-5-million-insider-buy
canonical_url: https://13finsight.com/news/bancel-mrna-ceo-5-million-insider-buy
published_at: 2026-03-01T10:37:02.965Z
updated_at: 2026-03-01T10:40:19.394Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 395
locale: en
source: 13F Insight
---

# Moderna CEO Stephane Bancel Bought $5 Million in MRNA Stock at $31 — His First Open-Market Purchase

> After selling $1.19 billion in Moderna shares since 2008, CEO Stephane Bancel reversed course and bought 160,000 shares at ~$31 in March 2025 — a rare bullish signal at multi-year lows.

Stephane Bancel, CEO of Moderna (MRNA), bought $5.2 million worth of company stock in March 2025 — his first open-market purchase on record. The buy came at a price of roughly $31 per share, near the stock's multi-year low and a 93% decline from its 2021 pandemic highs above $450. After years of systematic selling totaling $1.19 billion, the reversal is a striking signal from an insider who knows the company's pipeline better than anyone. The Numbers Metric Value Career Sell Value $1.19 billion Career Buy Value $5.2 million Total Transactions 1,701 First Transaction Aug 25, 2008 Last Transaction Dec 11, 2025 Shares Remaining 6,181,970 Recent Activity Date Type Shares Price Est. Value Dec 11, 2025 Exercise 688,073 $10.90 $7.5M (options) Mar 3, 2025 Buy 57,493 $31.53 $1.81M Mar 3, 2025 Buy 102,821 $31.04 $3.19M Mar 1, 2025 Award 357,065 $30.96 — Feb 12, 2025 Tax 6,400 $30.93 $198K (tax) Feb 16, 2024 Sell 26,351 $88.88 $2.34M The headline event is Bancel's March 3, 2025 open-market purchases: 160,314 shares bought across two transactions at $31.04–$31.53, totaling $5 million in new investment. This came just days after receiving a 357,000-share stock award, suggesting conviction beyond standard compensation. In December 2025, he exercised 688,073 options at $10.90, converting vested derivatives into common stock — a routine execution, but one that brings his total holding to 6.18 million shares. What It Means CEO open-market buys are among the strongest insider signals tracked by professional investors, and for good reason: executives use their own money to buy shares they could acquire for free through options. Bancel's $5 million purchase is especially notable given his history. He had sold $1.19 billion in MRNA stock over 17 years — much of it during the pandemic windfall when the stock traded above $400. To then deploy $5 million of personal capital at $31, near an all-time trough, implies a CEO who believes the market is dramatically undervaluing the company's non-COVID pipeline, which includes cancer vaccines and respiratory combination shots in late-stage trials. What to Watch Whether Bancel adds to his position if MRNA continues to trade below $40 — repeat insider buys at depressed levels are the highest-conviction signal in the playbook Pipeline catalysts in 2025–2026: flu/COVID combo vaccine data, cancer vaccine (mRNA-4157) trial results, and RSV program updates Whether other Moderna insiders follow the CEO's lead with their own open-market purchases

---

Source: 13F Insight — https://13finsight.com/news/bancel-mrna-ceo-5-million-insider-buy
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-01T10:40:19.394Z